Home › Funds › Defilade Capital Management, L.P. › ELDN
Defilade Capital Management, L.P. position in ELDN
ELEDON PHARMACEUTICALS INC · Health Care
Defilade Capital Management, L.P. reported holding 3,525,338 shares of ELDN (ELEDON PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$13.9M, representing 1.86% of its reported portfolio and ranking #23 among its reported holdings. Defilade Capital Management, L.P. has disclosed ELDN holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Defilade Capital Management, L.P.'s ELDN position evolved
Defilade Capital Management, L.P. first disclosed a stake in ELDN in Q4 2025 at 3,290,450 shares (US$5.0M). The position peaked in Q2 2026 at 3,525,338 shares, worth US$13.9M. Across 3 filings, Defilade Capital Management, L.P. increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 3,525,338 shares valued at US$13.9M — a reduction of -38,789 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 3.29M | $4.97M | New |
| Q1 2026 | 3.56M | $10.98M | Add |
| Q2 2026 | 3.53M | $13.89M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ELDN and 13F data
ELDN (ELEDON PHARMACEUTICALS INC) is a Health Care company. 40 other funds we track also report a position in ELDN — the largest reported positions include BVF INC/IL (US$24.8M), Catalio Capital Management, LP (US$6.7M), SPHERA FUNDS MANAGEMENT LTD. (US$4.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ELDN
- BVF INC/IL 6.29M sh · $24.80M · Q2 2026
- Catalio Capital Management, LP 1.70M sh · $6.68M · Q2 2026
- SPHERA FUNDS MANAGEMENT LTD. 1.19M sh · $4.69M · Q2 2026
- 22NW, LP 636.36K sh · $2.51M · Q2 2026
- CM Management, LLC 575.00K sh · $2.27M · Q2 2026
More on Defilade Capital Management, L.P.
FAQ
How long has Defilade Capital Management, L.P. held ELDN?
Defilade Capital Management, L.P. has disclosed ELDN holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is Defilade Capital Management, L.P.'s current position in ELDN?
As of Q2 2026, Defilade Capital Management, L.P. holds 3.53M shares of ELDN (ELEDON PHARMACEUTICALS INC), valued at $13.89M, representing 1.86% of its reported portfolio and ranking #23.
Has Defilade Capital Management, L.P. been buying or selling ELDN?
In the latest 13F filing (Q2 2026), Defilade Capital Management, L.P. reduced its position in ELDN. The position peaked in Q2 2026 at 3.53M shares.
Which other funds hold ELDN?
Other major institutional holders of ELDN include BVF INC/IL, Catalio Capital Management, LP, SPHERA FUNDS MANAGEMENT LTD., among 40 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.